ABSTRACT
1
The 2004 World Health Organization (WHO) recommendations for the classification of lung cancer on small samples aimed to classify carcinomas into two major histologic groups: non-small cell carcinoma (NSCLC) and small cell lung carcinoma. 2 This classification required examination of the surgically resected tumor to make a more specific diagnosis regarding NSCLC subtype, particularly adenocarcinoma (ACA) and squamous cell carcinoma (SCC). With a better understanding of the molecular changes of NSCLC and the development of targeted therapies for different subtypes of pulmonary carcinomas, it became necessary to further subtype NSCLC on small samples. The International Association for the Study of Lung Cancer/American Thoracic Society/ European Respiratory Society (IASLC/ATS/ERS) proposed a new classification that addresses the role of cytology and small biopsies. 1, 3 This classification was endorsed by the 2015 WHO classification of lung cancer. 4 Regarding cytology and small biopsies, the recommendations are the following: if the morphologic features of ACA or SCC are present, the specimen should be diagnosed as ACA or SCC. If immunohistochemical (IHC) or histochemical studies are needed to achieve a specific diagnosis, the neoplasm should be classified as NSCLC favor ACA or favor SCC. If the morphologic features and IHC/histochemical profile are not conclusive, the neoplasm should be diagnosed as NSCLC-not otherwise specified (NOS). 1, 4 The significance of the use of this nomenclature to subdivide patients with lung cancer is not well studied in the cytology literature. Herein, we share our experience with the recommended nomenclature for NSCLC on cytology specimens and search for associations with morphologic features on resection specimens, molecular studies, and clinical staging.
Materials and Methods
After approval by the institutional review board at the Johns Hopkins Hospital, a search of the electronic pathology database system was performed to identify patients with a cytopathologic diagnosis of NSCLC including ACA, SCC, and NSCLC with both squamous and glandular features. A total of 209 cases of fine-needle aspiration (FNA) of lung and/or mediastinal lymph nodes from January 2013 to March 2016 were included. Matching surgical pathology biopsy specimens in 66 cases and surgical resection specimens in 18 cases were available.
Patients and Cytologic Specimens
A total of 209 cytology specimens with slides available for review from 204 patients over the previously defined 3-year period were included. Patient demographics are summarized in ❚Table 1❚. The specimens were obtained by endobronchial ultrasound (EBUS)-guided FNA in 168 cases, ultrasound (US)-guided transthoracic FNA in 31 cases, a combination of EBUS-guided and US transthoracic FNA in two cases, endoscopic US-guided FNA in two cases, computed tomography (CT)-guided FNA in one case, US-guided transcutaneous in one case, bronchial alveolar lavage (BAL) in one case, and bronchoscopic brushing in one case. The method of sampling was not specified in two cases. The tissues sampled included lung only in 37 cases, lung and mediastinal lymph nodes in 74 cases, mediastinal lymph node only in 84 cases, mediastinal lymph node and BAL in seven cases, lymph node in five cases, BAL only in one case, and bronchoscopic brushing only in one case.
Surgical Pathology Correlation
Surgical pathology (SP) specimens, including concurrent biopsy specimens and/or lung resection specimens, were available in 84 cases. Matching SP biopsy specimens were available in 66 cases. In 55 cases, there was concordance between the cytopathology and SP specimens. In 11 cases, no tumor was identified in the SP specimen. Eighteen patients underwent surgical resection (ACA, n = 12; NSCLC favor ACA, n = 2; SCC, n = 3; and NSCLC-NOS, n = 1).
Morphologic Review
A blinded review of cytologic specimens was performed by the senior author (E.F.R.). Cases were reclassified using well-established cytomorphologic criteria for ACA and SCC. 1, 4, 5 In brief, cytomorphologic features of ACA included characteristic architectural patterns such as flat sheets, three-dimensional cell balls, pseudopapillary/papillary architecture, or clusters with acinar structures. Cellular features of ACA included round/oval or cylindrical shape and abundant cytoplasm that could be granular, foamy, homogeneous, or with intracytoplasmic vacuoles. Nuclear features included finely granular chromatin with prominent nucleoli, hyperchromasia, grooves, or inclusions. Morphologic features of SCC included dense/opaque cytoplasm with well-defined cell borders, true keratinization seen on Papanicolaou stain, round to ovoid/elongated cellular contours, cytoplasmic tails, and centrally located, hyperchromatic nuclei with no nucleoli. When the morphologic features were ambiguous, the specimen was considered NSCLC favor ACA or favor SCC depending on the results of the IHC and/or histochemical stains. In patients with more than one specimen, the tumor was classified with the most precise diagnosis (ACA, followed by NSCLC favor ACA, followed by NSCLC-NOS).
Immunohistochemical and Histochemical Stains
IHC and/or histochemical (mucicarmine) stains were performed at the time of initial diagnosis at the discretion of the signing-out pathologist. Stainings were performed following clinical protocols validated in our IHC and histochemical laboratories. Antibodies for IHC included Napsin-A (clone IP64, dilution 800; Novacastra, Newcastle upon Tyne, UK), TTF-1 (clone 8G7G3/1, predilution; Ventana Medical Systems, Tucson, AZ), and p40 (clone moue/BC28, dilution 1:100; Biocare, Concord, CA). IHC tests were performed on automated instruments (BenchMark; Ventana Medical Systems) and on Leica-Bond instruments for Napsin-A (Bond III; Leica Microsystems, Bannockburn, IL). 
Molecular Testing
Molecular results were available in 137 specimens, including 114 cytology cases and 23 surgical pathology cases (22 lung biopsy specimens and one lobectomy). Molecular studies were attempted in 13 additional cytology cases, but there was insufficient material. In 10 of those cases, stains were used for diagnosis-specifically, two stains in four cases, three stains in two cases, and four or more stains in four cases.
Molecular studies were performed on formalin fixed, paraffin-embedded (FFPE) tissue blocks from endobronchial biopsy samples, transthoracic biopsy specimens, lobectomy, and cellblocks from cytology specimens. Molecular testing was performed at the time of initial diagnosis of NSCLC as part of the clinical workup using next-generation sequencing (NGS). In brief, NGS was conducted using AmpliSeq Cancer Hotspot Panel (version 2; Life Technologies, Carlsbad, CA) for targeted multigene amplification as described in previous publications. [6] [7] [8] [9] Protocols followed the manufacturer's instructions. The DNA input for targeted multigene polymerase chain reaction (PCR) was up to 30 ng. From January 2013 to April 2013, pulmonary ACA was tested for BRAF, EGFR, and KRAS genes, and reflex ALK fluorescence in situ hybridization (FISH) was performed if no mutations were found in the genes previously cited. After April 2013, the panel included AKT, BRAF, EGFR, ERBB2, KRAS, NRAS, PIK3CA, and ALK (lung cancer panel). At our institution, molecular testing is routinely performed on all cases of ACA, NSCLC favor ACA, and NSCLC in which molecular testing has not been performed.
Statistical Analysis
Fisher exact and χ 2 tests were used to compare categorical variables. All tests were two-sided with P values less than .05 considered statistically significant. Log rank sum and Kaplan-Meier curves were used to study differences in overall survival. Statistical tests were performed using JMP software version 10 (SAS Institute, Cary, NC).
Results

Classification of Cytology Specimens
The cytomorphology and use of IHC stains were reviewed, and cases were classified according to the criteria defined in the Materials and Methods as ACA (n = 115), favor ACA (n = 43), and NSCLC-NOS (n = 18) ❚Image 1❚ and ❚Image 2❚. SCC (n = 14) and NSCLC favor SCC (n = 19) were excluded from further analysis. Overall, IHC/histochemical stains were performed in 124 (59.3%) of 209 cases. The number of stains used per case ranged from one to 11, with an average of three stains per case. The use of TTF-1, Napsin-A, p40/p63, and mucicarmine is summarized in ❚Table 2❚.
Molecular Alterations in NSCLC
Eighty-five cases with ACA morphology had molecular results as follows: mutations in EGFR (n = 26), KRAS (n = 26), EGFR and PIK3CA (n = 1), KRAS and PIK3CA (n = 1), BRAF (n = 1), and ALK (n = 1). No mutations were detected in 29 cases. Thirty-four cases with NSCLC favor ACA had the following molecular results: mutations in EGFR (n = 9), KRAS (n = 10), BRAF (n = 1), ALK (n = 1), and ERB2 (n = 1). No mutations were detected in 12 cases. Eighteen cases with an NSCLC-NOS diagnosis had the following molecular results: mutations in EGFR (n = 2), KRAS (n = 5), and ALK (n = 1). No mutations were detected in 10 cases ❚Figure 1❚.
Morphologic Features of NSCLC Subgroups on Cytology and Surgical Resections
Cases classified as ACA and NSCLC favor ACA and NSCLC-NOS on cytology specimens were compared regarding morphologic subclassification on surgical specimens, molecular findings, and staging. Twelve resection specimens were available for review (ACA, n = 10; NSCLC favor ACA, n = 1; NSCLC, n = 1). In © American Society for Clinical Pathology the 10 cases of ACA on cytology, the resection specimens showed ACA with an acinar pattern and associated papillary (n = 3), solid (n = 2), micropapillary (n = 2), or lepidic (n = 1) patterns. Two cases were posttreatment, and subclassification was not possible. In the specimen with morphologic features of NSCLC favor ACA on cytology, the resection showed acinar and papillary patterns. The specimen with NSCLC morphology on cytology showed ACA on the resection specimen with solid, papillary, and acinar patterns.
Comparison of Clinicopathologic and Molecular Features of NSCLC Subgroups
Clinical stage was available in 88 patients with tumors showing ACA morphology on cytology. Staging in this group included IA (n = 4), IB (n = 1), IIA (n = 2), IIB (n = 3), IIIA (n = 16), IIIB (n = 5), and IV (n = 57). In 36 patients with tumors showing NSCLC favor ACA morphology, clinical staging was known and included IA (n = 1), IB (n = 1), IIA (n = 1), IIB (n = 1), IIIA (n = 5), IIIB (n = 3), and IV (n = 24). In the NSCLC-NOS group, clinical staging was known in 17 patients and included IIA (n = 1), IIIA (n = 2), IIIB (n = 1), and IV (n = 13). When patients were grouped in stages I to II, III, and IV and the three groups were compared (ACA vs NSCLC favor ACA vs NSCLC-NOS), there were no differences in clinical staging (P = .9). There was no difference in the frequency of EGFRmutated and EGFR wild-type tumors when the three groups were compared (ACA vs NSCLC favor ACA vs NSCLC-NOS) (P = .21). In addition, there was no difference in the frequency of EGFR mutations vs other mutations in the three groups (P = .3) or the presence of tested mutations vs nonmutated tumors (P = .48). However, patients with known mutations had a longer survival than patients with no known mutations (median, 30.2 months vs 14 months, respectively) (P = .03). Patients with EGFRmutated tumors (median, 24.4 months) showed a longer overall survival than patients with EGFR wild-type tumors (median, 15.7 months) (P = .01). Patients with EGFRmutated tumors also showed a longer survival than patients with other mutations (20.6 months) (P = .04).
The overall mean survival for patients with ACA, NSCLC favor ACA, and NSCLC-NOS on cytology was 26.6 months, 21.8 months, and 3.1 months, respectively. There was no statistical difference among the groups (log rank P = .6).
Discussion
The current recommendation for small biopsy and cytology specimens is to classify NSCLC into specific categories, such as ACA and SCC. 1, 3, 4, 10 The IASCL/ ATS/ERS classification of cytology and small biopsy specimens recommends the terms ACA or SCC if no IHC or histochemical studies (mucin stain) were used to achieve the diagnosis and NSCLC favor ACA or favor SCC if stains were used to establish the diagnosis. However, the clinical and biologic significance of this change in the designation in small pathology samples is not entirely clear. Shiran et al 11 reported their experience with patients with ACA morphology. The ACA group showed a better prognosis and patients were diagnosed at earlier stages (I, II, and III) compared with the NSCLC favor ACA group on biopsy material. Other investigators have found comparable results regarding differentiation and prognosis, specifically when grading according to the predominant histologic architecture. 12 However, these studies were not performed using strictly cytology samples where morphologic features of ACA, such as three-dimensional cell arrangements as well as cytoplasmic and nuclear details, are more frequently present than in small biopsy specimens. 13, 14 Although the current WHO Classification of Tumours of the Lung, Pleura, Thymus and Heart 4 supports the use of this nomenclature, it may not be applicable to cytology specimens due to better recognition of morphologic features of ACA in most of the tumors examined.
Cytologic evaluation has emerged as an accurate method for subtyping NSCLC. [13] [14] [15] [16] However, scant cellularity, poor differentiation, necrosis, or cases that have solid pattern-like features can lead to challenges in diagnosing ACA due to a squamoid appearance. 13, 14, 17 The use of IHC has been shown to increase interobserver agreement and accuracy of diagnosis in NSCLC, 18 and furthermore, specific IHC panels have been recommended. Most authors suggest the use of squamous cell IHC markers such as CK5/6, p63, or p40 and ACA markers such as TTF-1 and Napsin-A. [19] [20] [21] [22] The use of dual staining has been applied to the cytopathologic evaluation of NSCLC and will likely be a useful approach going forward, especially for specimens with scant cellularity. [23] [24] [25] [26] However, IHC use and histochemical staining are variable among pathologists/institutions. In our study, IHC/stains were performed in 59.3% of the cases at the time of initial diagnosis, although upon review, the cytomorphologic criterion of ACA or SCC was present in 61.7% of the cases. This falls between the frequency reported by Sigel et al 13 of 6% and Esterbrook et al 27 of 73%. In the current study, we did not observe a difference between molecular alterations by NSCLC subgroups. One caveat of our study is that a subset of patients tested prior to April 2013 had fewer genes analyzed as per standard of care at that time. However, this should not significantly affect our conclusions, particularly when focusing on the most relevant genes (eg, EGFR, RAS, and ALK) since both panels were extensively validated for clinical use and reported in an analogous way in multiple publications. [6] [7] [8] [9] In our study, we did not find differences in outcome or molecular alterations in the three NSCLC subgroups (ACA, NSCLC favor ACA, and NSCLC-NOS). The mean overall survival for NSCLC-NOS was lower than the other two groups, but this did not reach statistical significance. This could be due in part to the relatively small number of NSCLC-NOS compared with the other groups. Alternatively, tumors with SCC features were intentionally ❚Image 2❚ (cont) The neoplastic cells are positive for TTF-1 (×40)(E) and Naspsin-A (×40) (F).
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In summary, ancillary testing is frequently performed in most NSCLC cytology cases at our institution despite the presence of specific morphologic features of ACA or SCC. An important result from our study is that the presence of cytomorphologic features of ACA had no association with survival, staging, or molecular results. However, future studies may further clarify the clinical implications of subdividing pulmonary NSCLC in cytology and biopsy specimens to improve diagnostic accuracy and patient management.
